POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).							
I hereby appoint:							
X p	ractitioners associated	d with the Customer Number:	78018				
OR							
Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):							
	Name		Registration Na		Name	Registration Number	
-			Nemise:			IVanibei	
-							
as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with							
any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).							
Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:							
	The address associated with Customer Number: 78018						
	OR						
	Firm or Individual Name						
Address .							
City	ty		State		Zip		
Count	Country						
Telepi	Telephone			Email			
نـــا		•		İ			
Assigne	e Name and Address:						
	Novartis A	G					
Basel, Switzerland							
A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be							
filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of							
the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.							
SIGNATURE of Assignee of Record The individual whose signature and title is supplied below is authorized to act on behalf of the assignee							
Signatu	e /Dean	/Dean Nakamura/			Date 5 February 2009		
Name	Dean Nakamura				Telephone 2024126986		
Title	Agent						
			4 22 The information		state a honofit by the nublic	. Alab is to Ct. Jane	

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to lake 3 minutes to complete, including gathering, preparing, and submitting the completed opplication form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)							
Applicant/Patent Owner: Novartis AG							
Application No./Patent No.: 10529428 Filed/	Issue Date: 9 November 2006						
Entitled: Potassium channel mutants of the yeast Saccharomyces cerevisiaeeukaryotic potassium channels							
Novartis AG , a, a	corporation pe of Assignee, e.g., corporation, partnership, university, government agency, etc.)						
states that it is:	po ar, resignost organ emperation, portationally, annually, government egotier, etc.,						
1. The assignee of the entire right, title, and interest; or							
2. an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is%)							
in the patent application/patent identified above by virtue of either:							
A An assignment from the inventor(s) of the patent appli in the United States Patent and Trademark Office at R thereof is attached.	cation/patent identified above. The assignment was recorded leel, Frame, or for which a copy						
OR B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:							
	T-1.						
From: To: The document was recorded in the United States Patent and Trademark Office at							
Reel, Frame	, or for which a copy thereof is attached.						
From: The document was recorded in the United State	To:						
The document was recorded in the United Stat	tes Patent and Trademark Office at, or for which a copy thereof is attached.						
3. From:	To:						
3. From:							
Reel, Frame, or for which a copy thereof is attached.							
Additional documents in the chain of title are listed on a supplemental sheet.							
As required by 37 CFR 3.73(b)(1)(i), the documentary of assignee was, or concurrently is being, submitted for record	evidence of the chain of title from the original owner to the ation pursuant to 37 CFR 3.11.						
[NOTE: A separate copy (i.e., a true copy of the original Division in accordance with 37 CFR Part 3, to reco 302.08]	I assignment document(s)) must be submitted to Assignment rd the assignment in the records of the USPTO. <u>See</u> MPEP						
The undersigned (whose title is supplied below) is authorize	ed to act on behalf of the assignee.						
/Dean Nakamura/	9 February 2009						
Signature	Date						
Dean Nakamura, Reg. No. 33981	202.412.6986						
Printed or Typed Name	Telephone Number						
Agent/Attorney							
Title							

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ASSIGNMENT

Attorney Docket No.: 010804-22190200

WHEREAS <u>Peter Anthony CAMPOCHIARO and Michael KALEKO</u>, hereinafter referred to as the Assignors, have invented a certain improvement relating to <u>OCULAR</u> <u>GENE THERAPY</u>, which said Assignors have caused an application for United States Letters Patent to be prepared, said application having been filed in the United States Patent and Trademark Office on <u>25 March 2005</u>, having serial number <u>10/529,428</u>, which arose from PCT Ser. No. <u>EP2003/010725</u> filed <u>26 September 2003</u>, which claims benefit to U.S. Ser. No. <u>60/414,048</u> filed <u>27 September 2002</u>;

WHEREAS <u>NOVARTIS AG</u>, <u>Lichstrasse 35</u>, <u>CH-4056 Basel</u> hereinafter referred to as the Assignee, is desirous of acquiring the entire right, title and interest in and to said applications, including any and all divisions and continuations thereof, and in and to said invention and any and all patents which may be granted therefore, including any and all renewals, reissues, parental applications and prolongations thereof;

NOW, WITNESSETH, that for and in consideration of One Dollar (\$1.00), and other good and valuable consideration paid by Assignee to Assignors, the receipt and sufficiency of which is hereby acknowledged, Assignors, nunc pro tunc, hereby assign, sell and transfer, and has assigned, sold, and transferred to Assignee, its successors and assigns, the entire and exclusive right, title, and interest for the United States in and to the invention, the US application, the PCT application and the provisional application (noted above), and any patents which may be granted therefor, including any and all divisions, continuations, in whole or in part, substitutions, renewals, reissues, reexaminations, and extensions thereof, and all applications claiming priority therefrom; and Assignor authorizes and requests the Commissioner of Patents and Trademarks to issue all patents for the invention, or patents resulting therefrom, insofar as their interest is concerned, to Assignee; to have, hold, exercise, and enjoy, with all the rights, powers, privileges, and advantages in anywise arising therefrom or appertaining thereto, for and during the term or terms of any and all such patents when granted, for the use and benefit of sald Assignee, and said successors and assigns of sald Assignee, in as ample and beneficial a manner as Assignors might or could have held and enjoyed the same, if this assignment had not been made.

Assignors further, nunc pro tunc, hereby assign, sell and transfer, and have assigned, sold, and transferred to Assignee, its successors and assigns, the entire right, title and interest in all countries of the world, in and to the invention and in and to the application and the parental applications noted herein, and all patents which may be granted therefor, and all national applications, regional applications, divisions, reissues, substitutions, continuations, in whole or in part, re-examinations, and extensions thereof, including the right to file applications and obtain patents for the invention in its own name, in all countries and including all rights of priority in all countries under the terms of any applicable international convention, insofar as its interest is concerned; and the Assignors hereby authorize and request the applicable patent office in each country of the world to issue all patents for the invention, or patents resulting thereform, insofar as its interest is

ASSIGNMENT

Page 2

concerned, to the Assignee, to have and to hold for the sole and exclusive use and benefit of the Assignee, its successors and assigns, to the full end of the term or terms for which any and all of such patents for the invention may issue, to the same extent as the Assignors would hold and enjoy if this Assignment had not been made.

The Assignors further agree to execute any and all patent applications, assignments, affidavits, and any other papers in connection therewith necessary to perfect such patent rights, and also agree, at the request of the Assignee, to testify in any legal proceedings, sign all lawful papers, make all lawful oaths, and generally do everything possible to aid said Assignee, its successors and assigns, to obtain, maintain and enforce proper patent protection for said invention.

Signature:

Name:

Date:

Signature:

Name: Date:

LEKO

01518c44